ContraFect Announces Lopsided Interim Results From Pivotal Bacterial Infection Study
- ByBenzinga-
Benzinga - ContraFect Corporation (NASDAQ: CFRX) has announced the database lock of its Phase 3 DISRUPT study of exebacase in patients with Staph aureus bacteremia, along with a...